US2013090294A1PendingUtilityA1

Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders

38
Individually held — no corporate assignee on recordPriority: Jun 28, 2011Filed: Jun 28, 2012Published: Apr 11, 2013
Est. expiryJun 28, 2031(~4.9 yrs left)· nominal 20-yr term from priority
Inventors:Sergei B. OnikienkoAlex NivorozhkinAlexander V. Zemlyanoi
A61P 21/00A61K 38/1703A61K 38/17A61K 47/60
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A formulation comprising HSP70, and pharmaceutically acceptable carrier. 
     
     
         2 . The formulation of  claim 1  comprising a therapeutically effective amount of HSP70. 
     
     
         3 . The formulation of 1, formulated for intravenous, subcutaneous, intranasal, oral, or inhalation administration. 
     
     
         4 . The formulation of any one of  claims 1 , wherein the HSP70 is recombinant human HSP70. 
     
     
         5 . The formulation of any one of  claims 1 , wherein the HSP70 is pegylated HSP70. 
     
     
         6 . The formulation of any one of  claims 1 , wherein the amount of the heat shock protein 70 present in the composition is in a range of 0.1 to 10 milligrams. 
     
     
         7 . A method of treatment of an HSP70 related disorder or condition, wherein the method comprises administering to a subject a therapeutically effective amount of HSP70, such that the HSP70 related disorder or condition is treated in the subject. 
     
     
         8 . A method to increase performance, alleviate fatigue syndrome, or treat muscle damage or muscle degeneration comprising administering to a mammal a therapeutically effective amount of HSP70, such that performance is increased, the fatigue syndrome is alleviated, or the muscle damage or muscle degeneration is treated in the mammal. 
     
     
         9 . The method of  claim 7 , wherein the HSP70 human heat shock protein 70. 
     
     
         10 . The method of  claim 7 , wherein the HSP70 is pegylated HSP70. 
     
     
         11 . The method of  claim 7 , wherein the mammal is human. 
     
     
         12 . The method  claim 7 , wherein the formulation is administered intravenously, subcutaneously, intranasally, orally, or by inhalation. 
     
     
         13 . The method of  claim 8 , wherein the HSP70 human heat shock protein 70. 
     
     
         14 . The method of  claim 8 , wherein the HSP70 is pegylated HSP70. 
     
     
         15 . The method of  claim 8 , wherein the mammal is human. 
     
     
         16 . The method  claim 8 , wherein the formulation is administered intravenously, subcutaneously, intranasally, orally, or by inhalation.

Join the waitlist — get patent alerts

Track US2013090294A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.